FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
PO62 | CLINICAL AND MOLECULAR DIAGNOSTIC CHALLENGES IN MYELOPROLIFERATIVE NEOPLASMS WITH LOW JAK2V617F ALLELIC BURDEN E. Morsia, D. Lame, M. Pianelli, G. Gramazio, R. Ceccarelli, I. Battilà, S. Rupoli, A. Poloni | Department of Clinical and Molecular Science, Università Politecnica delle Marche, Ancona, Italy
362PDF: 94 -
PO55 | HISTORY OF CANCER IN PATIENTS WITH SEVERE HEREDITARY THROMBOPHILIA VERSUS NO THROMBOPHILIA: A SINGLE-CENTER COHORT OF PATIENTS WITH VENOUS THROMBOSIS A. Napolitano, E. Campello, C. Simion, G. Furlan, S. Gavasso, C. Bulato, C. Samà, S. Toffanin, B. Serena, L. Spiezia, P. Simioni | Internal Medicine 1 and Thrombotic and Hemorrhagic Diseases Unit, Department of Medicine, University of Padova, Italy
367PDF: 98 -
PO10 | RISK OF VENOUS THROMBOEMBOLISM IN CANCER PATIENTS WITH CENTRAL VENOUS CATHETERS: RESULTS FROM THE VIENNA CAT-BLED STUDY B. Sunder-Plassmann 1, N, Vladic1, C. Englisch1, F. Moik1|3, V. Sunder-Plassmann2, A. Berghoff2, M. Preusser2, I. Pabinger1, C. Ay1 | 1Division of Hematology and Haemostaseology, Department of Medicine I, Medical University of Vienna; Vienna, Austria; 2Division of Oncology, Department of Medicine I, Medical University of Vienna; Vienna, Austria; 3Division of Oncology, Department of Internal Medicine, Medical University of Graz; Graz, Austria
325PDF: 80 -
PO36 | EXTENDED DURATION REDUCED DOSE ANTICOAGULATION IN CANCER-ASSOCIATED THROMBOSIS: A REAL-WORLD COHORT WITH LONG TERM FOLLOW UP A. Bhide1, I. Welding1, O. Ogunbiyi1, S. Hawkins2, E. Greenlay1, N. Prasannan1, J. Westwood1, M. Thomas1 | 1Department of Clinical Haematology, University College London Hospital, London; 2Data Clinic, University College London, UK; A. Bhide and I. Welding joint First Authors
332PDF: 93 -
Welcome to the 12th International Conference on Thrombosis and Hemostasis Issues in Cancer! Oral Communications and Posters
851PDF: 545 -
PO53 | PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF REGN7508CAT FOR PRIMARY PROPHYLAXIS OF CANCER-ASSOCIATED THROMBOSIS FOR PARTICIPANTS WITH SOLID TUMORS UNDERGOING CANCER TREATMENT (ROXI-CAT-I) J. Zwicker1, M. P. O’Brien2, M. Carrier3, J. Connors4, A. Falanga5, A. Manzano6, R. Mcbane7, Y.Y. Janjigian1, G. O’Kane8, M. Onisko2, J. Kaplan2, A.P. Kithcart2, D.E. Gutstein2, A. Khorana9, M. F. Walsh2 | 1Memorial Sloan Kettering Cancer Center, New York, USA; 2Regeneron Pharmaceuticals, Inc. , Tarrytown, NY, USA; 3University of Ottawa, Ottawa, ON, Canada; 4Harvard Medical School, Boston, MA, USA; 5Hospital Papa Giovanni XXIII, Bergamo, Italy; 6Hospital Universitario 12 de Octubre, Madrid, Spain; 7Mayo Clinic, Rochester, MN, USA; 8St. Vincent's University Hospital and School of Medicine, University College Dublin, Dublin, Ireland; 9James P. Wilmot Cancer Center and the Department of Medicine, University of Rochester, Rochester, NY, USA
328PDF: 97 -
PO09 | CANCER MORTALITY AFTER INCIDENT VENOUS THROMBOEMBOLISM C. Langholm1, N.H. Eide1, K. Hveem2|3|4, N. Van Es5|6, V.M. Morelli1|7, S.K. Braekkan1|7, J.B. Hansen1|7 | 1Thrombosis Research Group, Department of Clinical Medicine, UiT – The Arctic University of Norway, Tromsø, Norway; 2HUNT Research Centre, Department of Public Health and General Practice, Norwegian University of Science and Technology, Levanger, Norway; 3HUNT Center for Molecular and Clinical Epidemiology, Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway; 4Department of Research, St. Olav University Hospital, Trondheim, Norway; 5Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands; 6Amsterdam Cardiovascular Sciences Pulmonary Hypertension and Thrombosis Amsterdam, the Netherlands; 7Thrombosis Research Center, Department of Internal Medicine, University Hospital of North Norway, Tromsø, Norway
322PDF: 59 -
PO32 | ANTICOAGULANT THROMBOPROPHYLAXIS IN AGGRESSIVE LYMPHOMAS PATIENTS: PREDICTIVE THROMBOTIC RISK SCORES AND RISK FACTORS L. Gurgoglione1, G. Gini1, S. Rupoli1, A. Poloni1|2 | 1Hematology, AOU delle Marche, Ancona; 2Università Politecnica delle Marche, Ancona, Italy
361PDF: 74 -
PO52 | MECHANISTIC POPULATION PHARMACOKINETIC/PHARMACODYNAMIC AND TIME-TO-EVENT MODELING SUPPORT SUSTAINED FACTOR XI INHIBITION AND SUPERIOR POST-OPERATIVE VENOUS THROMBOEMBOLISM PREVENTION WITH REGN7508CAT O. Milberg1, H. Abdallah1, R.K. Lokken2, R. Dingman1, K.A. Meagher1, P. Banerjee1, M.E. Burczynski1, E. Marin1, A.P. Kithcart1, D.E. Gutstein1 | 1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; 2Allucent, Cary, NC, USA
368PDF: 100 -
OC09 | BLEEDING RISK ASSOCIATED WITH FACTOR XI MONOCLONAL ANTIBODIES IN COMBINATION WITH ASPIRIN IN HEALTHY VOLUNTEERS AND ORTHOPEDIC SURGERY PATIENTS: ANALYSIS FROM RECENT PHASE 1 AND PHASE 2 STUDIES A.P. Kithcart1, M.E. Burczynski1, P. Banerjee1, M. Onisko1, Y. Wang1, K. Mohammadi1, D. Li1, S. Li1, J. Ackroyd2, B.A. Olenchock1, D.E. Gutstein1, J. I. Weitz3 | 1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; 2Clinical Research, Fortrea Clinical Research Unit Ltd, Leeds, UK; 3McMaster University, Hamilton, ON, Canada
320PDF: 84 -
PO68 | RISK OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH CANCER AND MIGRAINE: A COHORT ANALYSIS AMONG DANISH NATIONAL HEALTH SURVEY PARTICIPANTS O. Rosenkrantz1, P. Szentkúti1, L. Amdisen1, E. Horváth-Puhó1, A.L. Pedersen1, H.E. Bøtker2, H. Elser1|3, J.P. Vandenbroucke1|4|5, H.T. Sørensen1 | 1Department of Clinical Epidemiology and Center for Population Medicine, Aarhus University Hospital and Aarhus University, Denmark; 2Department of Cardiology, Aarhus University Hospital, Department of Clinical Medicine, University of Aarhus, Denmark; 3Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA; 4Department of Clinical Epidemiology, Leiden University Medical School Leiden, The Netherlands; 5School of Hygiene and Tropical Medicine, London, UK
363PDF: 94 -
PO28 | CLINICAL IMPLICATIONS OF ANTICOAGULANT DRUG INTERACTIONS WITH TARGETED AND IMMUNE THERAPIES IN ONCOLOGY: A CONTEMPORARY RISK STRATIFICATION FRAMEWORK D. Dhami1, C. Solowiej Singh 1, M. Dhami 2 | 1Abrazo Internal Medicine Residency; 2Eastern Connecticut Hematology Oncology, Norwich, CT, USA
375PDF: 80 -
PO51 | MECHANISTIC POPULATION PHARMACOKINETIC/PHARMACODYNAMIC MODELING OF FACTOR XI-TARGETING MONOCLONAL ANTIBODIES SUPPORTS DURABLE ANTICOAGULANT COVERAGE AND TRANSLATIONAL DOSE AND REGIMEN SELECTION O. Milberg1, H. Abdallah1, R.K. Lokken2, R. Dingman1, K.A. Meagher1, M.E. Burczynski1, E. Marin1, A.P. Kithcart1, D. E. Gutstein1 | 1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; 2Allucent, Cary, NC, USA
334PDF: 101 -
OC05 | TIME TO START OF ANTICOAGULANT THERAPY AND SURVIVAL OUTCOMES IN CANCER PATIENTS WITH PULMONARY EMBOLISM K. Bria, B. Gage, M. Bealsey, K. Sanfilippo | Washington University in St. Louis School of Medicine, St. Louis, MO, USA
334PDF: 81 -
PO26 | OUTCOMES OF DIRECT ORAL ANTICOAGULANTS IN UNUSUAL-SITE THROMBOSIS: IMPACT OF ACTIVE CANCER S. Guglielmo1, M. Lovisotto1, L. Scarano1, E. De Bon2, S. Barbar2 | 1Internal Medicine, Department of Medicine, Azienda Ulss 6 Euganea, Cittadella (PD), Italy; 2Thrombotic and Hemorrhagic Disorders Unit, Department of Medicine, Azienda Ulss 6 Euganea, Cittadella (PD), Italy
337PDF: 93 -
PO50 | SUB-ANALYSIS OF INTERIM RESULTS FROM A PHASE 2 STUDY INVESTIGATING REGN9933A2 AND REGN7508CAT FOR THE PREVENTION OF CONTACT-MEDIATED VENOUS THROMBOEMBOLISM IN PATIENTS WITH ACTIVE CANCER UNDERGOING PERIPHERALLY INSERTED CENTRAL CATHETER PLACEMENT (ROXI-CATH) J. Zwicker1,2, A.P. Kithcart3, J. Kaplan3, Y-C. Cheng3, J.G. Raya3, J. Xiao3, S. Li3, K. Musgrave4, D.E. Gutstein3, G. Piazza5 | 1Memorial Sloan Kettering Cancer Center, New York, NY, USA; 2Weill Cornell Medical Center, New York, NY, USA; 3Regeneron Pharmaceuticals, Inc. , Tarrytown, NY, USA; 4Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; 5Brigham and Women’s Hospital, Boston, MA, USA
342PDF: 107 -
OC04 | DIRECT ORAL ANTICOAGULANTS PROVIDE EFFECTIVE THROMBOPROPHYLAXIS IN NEWLY DIAGNOSED MYELOMA: REAL WORLD FINDINGS FROM THE ATOMM STUDY T. Bull1, Heamstar Collaborators2, W. Wilson3, E. Ganendra4, M. Thomas5, R. Alikhan6, M. Karanth1, M. Camilleri7 | 1West Suffolk Hospital NHS Foundation Trust, UK; 2Haematology Specialty Training Audit and Research HaemSTAR Network, UK; 3University College London Clinical Trial Centre, UK; 4North West Anglia NHS Foundation Trust, UK; 5University College London Hospitals, UK; 6Cardiff and Vale University Health Board, Wales, UK; 7Cambridge University Hospitals NHS Foundation Trust, UK
431PDF: 93 -
PO57 | A NOVEL RISK ASSESSMENT MODEL FOR CANCER DETECTION WITHIN ONE YEAR AFTER INCIDENT VENOUS THROMBOEMBOLISM C. Antoun1, J. Hansen1|3, S. Brækkan1|3, C. Langholm1, N. Eide1, V. Morelli1|3, K. Hveem2 | 1Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø; 2HUNT Center for Molecular and Clinical Epidemiology, Norwegian University of Science and Technology, Trondheim; 3Thrombosis Research Center, Division of Internal Medicine, University Hospital of North Norway, Tromsø, Norway
354PDF: 87 -
PO18 | THE THROMBO-INFLAMMATION AXIS AS PREDICTOR OF TOXICITY IN PATIENTS TREATED WITH CAR-T CELLS C. Fernández-Arias1, M. Marcos-Jubilar1, M. Panizo1, C. Vázquez-Puerta2, J.R. González-Porras2, M. Ibáñez1, A. Queralt1, M. Carrasco1, M.B. Villacrés1, C. Conde1, P. Elizalde1, S. Huerga1, A. Alfonso1, P. Rodríguez-Otero1, S. Villar1, M.A. Canales1, J. Rifón1, F. Prósper1, J.A. Páramo1, J. Orbe1, R. Lecumberri1 | 1Clínica Universidad de Navarra, Pamplona; 2Hospital Clínico Universitario de Salamanca, Salamanca, Spain
370PDF: 70 -
PO45 | KHORANA RISK SCORE AND GENOMIC PROFILING FOR PREDICTION OF VENOUS THROMBOEMBOLISM IN OVARIAN CANCER P. Santini, L. Mastrantoni, G. Anderson, F. Camarda, I. Marino, J. Preziosi, M. Buttarelli, M. Manfredelli, A. Minucci, F. Persiani, L. Giacò, T. Pasciuto, I. Conti, I. Mozzetta, F. Mancinetti, S. M. P. D’Ambrosio, M. Bigossi, C. Marchetti, V. Salutari, G. Scambia, C. Nero, R. Pola | Agostino Gemelli University Hospital Foundation IRCCS, Rome, Italy
320PDF: 96 -
OC02 | INCIDENCE AND PREDICTORS OF ARTERIAL THROMBOSIS IN CANCER PATIENTS: RESULTS FROM THE PROSPECTIVE COMPASS-ARTERIAL CANCER ASSOCIATED THROMBOSIS (COMPASS-ARTECAT) STUDY M. Drakopoulou1, I. Diamandoulaki2, P. Baglaridis1, P. Las Casa3, P. Van Dreden4, K. Toutouzas1, G. Gerotziafas4|5 | 1First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital, Athens, Greece; 2Department of Electrical and Computer Engineering, Aristotle University of Thessaloniki, Thessaloniki, Greece; 3Sorbonne University, INSERM UMR_S_938, CRSA, Research Department "Cancer, Vessels, Biology and Therapeutics" (CaVITE), Research Group "Cancer-Angiogenesis-Thrombosis and Haemostasis," Thrombosis Center, University Institute of Cancerology (UIC), Saint Antoine University Hospital Assistance Publique Hôpitaux de Paris (AP-HP) Paris France; 4Diagnostica Stago, clinical research, Gennevilliers, France; 5Center of Translational Research and Education, Department of Pathology and Laboratory Medicine, Loyola University Stritch School of Medicine, Maywood, Ill., USA
349PDF: 92 -
PO56 | EXTERNAL VALIDATION OF THE SAVED SCORE IN A CANADIAN REGIONAL CANCER CENTER COHORT: A REAL-WORLD ANALYSIS A. Naassan, R. Fatima, M. Naassan, C. Chisholm | Lakeridge Health, R.S. McLaughlin Durham Regional Cancer Centre, Department of Oncology, Oshawa, ON, Canada
580PDF: 107 -
PO12 | IMPACT OF INHERITED THROMBOPHILIA ON CANCER-ASSOCIATED THROMBOSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS E. Campello1, G. Furlan1, A. Boccatonda2, A. Napolitano1, C. Simion1, P. Simioni1 | 1Internal Medicine 1 and Thrombotic and Hemorrhagic Diseases Unit, Department of Medicine, University of Padova, Italy; 2Diagnostic and Therapeutic Interventional Ultrasound Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola-Malpighi, Bologna, Italy
326PDF: 77 -
PO37 | CLINICAL SIGNIFICANCE OF SYMPTOMATIC AND INCIDENTAL VENOUS THROMBOEMBOLISM IN CANCER PATIENTS TREATED WITH APIXABAN P. Hussaini1, T.L. Larsen2, W. Ghanima1|3, A.E.A. Dahm1|2 | 1Institute of Clinical Medicine, University of Oslo, Oslo, Norway; 2Department of Hematology, Akershus University Hospital; Lørenskog, Norway; 3Clinic of Internal Medicine, Østfold Hospital, Grålum, Norway
293PDF: 92
1 - 26 of 26 items
